21.05.2015 • NewsDede WillamsJohnson & JohnsonJanssen

J&J Drugs Arm Announces 10 Blockbuster Filings by 2019

Johnson & Johnson's Janssen Pharmaceuticals offshoot has told analysts it plans to seek regulatory approval for more than 10 new drugs up to 2019, each with the potential to generate at least $1 billion annual sales.

This would come in addition to more than 40 line extensions of existing and new medicines. The US pharmaceutical major said it expects top-line growth above the industry average through 2019.

Janssen's portfolio focuses on the five core therapeutic areas: immunology; infectious diseases & vaccines; neuroscience; cardiovascular & metabolism and oncology.

Since 2009, the drugmaker has launched 14 new products, seven of which are expected to achieve blockbuster status this year, with sales of more than $1 billion.

Late stage products in the Janssen pipeline include daratumumab for multiple myeloma, sirukumab for rheumatoid arthritis, guselkumab for psoriasis, JNJ-927 (ARN0509) for pre-metastatic prostate cancer, imetelstat for myelofibrosis, JNJ-493 for urothelial cancer, esketamine for treatment-resistant depression and AL-8176 for hepatitis C.

In February of this year, the company announced the launch of three new research platforms focused on disease prevention, disease intervention and the microbiome, with the intent to potentially change the way diseases are managed.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.